KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Accumulated Expenses (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Accumulated Expenses for 14 consecutive years, with $2.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses changed N/A year-over-year to $2.0 million, compared with a TTM value of $2.0 million through Sep 2025, changed N/A, and an annual FY2024 reading of $118000.0, down 96.23% over the prior year.
  • Accumulated Expenses was $2.0 million for Q3 2025 at TherapeuticsMD, up from $200000.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $51.7 million in Q3 2021 and bottomed at $118000.0 in Q4 2024.
  • Average Accumulated Expenses over 4 years is $12.7 million, with a median of $2.0 million recorded in 2025.
  • The sharpest move saw Accumulated Expenses soared 3172.64% in 2021, then plummeted 96.23% in 2024.
  • Year by year, Accumulated Expenses stood at $2.0 million in 2021, then soared by 57.04% to $3.1 million in 2023, then tumbled by 96.23% to $118000.0 in 2024, then skyrocketed by 1607.63% to $2.0 million in 2025.
  • Business Quant data shows Accumulated Expenses for TXMD at $2.0 million in Q3 2025, $200000.0 in Q2 2025, and $1.8 million in Q1 2025.